Goodyear Tire & Rubber Co vs Personalis Inc. Common Stock — how do they compare? Goodyear Tire & Rubber Co trades at $4.48 (market cap $1.26B), while Personalis Inc. Common Stock trades at $15.96 (market cap $1.70B). The key difference: Personalis Inc. Common Stock is the larger of the two by market cap, and Personalis Inc. Common Stock is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 58 Days and Personalis Inc. Common Stock for 0 Days on average.
| GT | PSNL | |
|---|---|---|
Market Cap | $1.26B | $1.70B |
Volume | 7,768,478 | 3,262,398 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $18.38 |
52-Week Low | $4.38 | $5.04 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | $8.61B | $1.52B |
Signals from Pluang's Aura AI — not financial advice
GT trades at $4.56, up 1.56% on the day, but remains in a bearish technical trend with the stock near its 52-week low. The company reported a net loss of $1.72 billion in 2025, with negative profit margins and ROE, though it beat Q1 and Q2 2026 EPS estimates. Cash flow from operations improved to $796 million in 2025, but high debt levels and restructuring efforts under a new strategy are key focal points.
The outlook is challenged by persistent losses and volume pressure, but analyst consensus suggests upside with a $8.00 price target. Investment opportunity hinges on successful execution of the margin-focused turnaround; key risks include execution missteps, competitive pressures, and macroeconomic headwinds affecting tire demand.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →